Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iRadimedFRA:46K +1.35%94 EV-to-EBIT is 38.90 as of Aug. 19, 2026, which is 21% above its 10-year median of 32.27. GuruFocus rates FRA:46K with a GF Score™ of 94/100 and a GF Value™ of €56.42 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 472 Medical Devices & Instruments companies, iRadimed ranks worse than 79.66% on this metric.
The historical rank and industry rank for iRadimed's EV-to-EBIT or its related term are showing as below:
FRA:46K'
s EV-to-EBIT Range Over the Past 10 Years
Min: -352.53 Med: 32.27 Max: 1120.39
Current: 38.73
During the past 13 years, the highest EV-to-EBIT of iRadimed was 1120.39. The lowest was -352.53. And the median was 32.27.
FRA:46K's EV-to-EBIT is ranked worse than 79.66% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 19.185
vs FRA:46K: 38.73
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
iRadimed's Enterprise Value for the quarter that ended in Jun. 2026 was €990.86 Mil.
iRadimed's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €23.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iRadimed EV-to-EBIT Related Terms
iRadimed EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for iRadimed's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:46K vs AORT, TNDM, AVNS: EV-to-EBIT Comparison
For the Medical Devices subindustry, iRadimed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iRadimed EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iRadimed's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where iRadimed's EV-to-EBIT falls into.
iRadimed's current Enterprise Value is €921.51 Mil.
iRadimed's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €23.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iRadimed (FRA:46K) has a EV-to-EBIT of 38.90 as of Aug. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on iRadimed and its competitors. This is 21% above median its historical median of 32.27. According to the industry distribution chart, iRadimed ranks #376 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 79.7%.
Is iRadimed's EV-to-EBIT too high?
iRadimed's current EV-to-EBIT of 38.90 is 21% above median its 10-year median of 32.27. The Medical Devices & Instruments industry median EV-to-EBIT is 19.19. iRadimed's value of 38.90 is 102.8% above this industry median. Based on the distribution chart, iRadimed ranks #376 out of 472 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, iRadimed has a GF Score™ of 94/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iRadimed's EV-to-EBIT compare to AORT and TNDM?
According to the Medical Devices & Instruments industry distribution chart, iRadimed ranks #376 out of 472 companies for EV-to-EBIT. This places iRadimed in the lower half of its industry. The industry median EV-to-EBIT is 19.19. iRadimed's value of 38.90 is 102.8% above this benchmark. While the company's 10-year median is 32.27 vs. the industry median of 19.19, iRadimed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.19, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iRadimed's current EV-to-EBIT of 38.90 is 102.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on iRadimed and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iRadimed's current EV-to-EBIT is 38.90, which is 21% above median its own 10-year median of 32.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRadimed stock overvalued right now?
Based on GuruFocus' analysis, iRadimed (FRA:46K) is currently considered Significantly Overvalued. The stock's GF Value™ is €56.42, compared to a current price of €75.00 — trading 32.9% above its estimated fair value. The current EV-to-EBIT is 38.90, which is 21% above median its 10-year median of 32.27 and 102.8% above the Medical Devices & Instruments industry median of 19.19. iRadimed's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For iRadimed (FRA:46K), the current EV-to-EBIT is 38.90 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iRadimed (FRA:46K) Overvalued in 2026?
Based on GuruFocus' analysis, iRadimed stock appears to be overvalued.
The current stock price of €75.00 is trading 32.9% above its estimated GF Value™ of €56.42.
GuruFocus considers iRadimed to be Significantly Overvalued.
Key valuation signals for FRA:46K:
EV-to-EBIT: 38.90 (21% above median its 10-year median of 32.27)
GF Value™: €56.42 vs. price of €75.00 (32.9% above fair value)
Industry Position: 102.8% above the Medical Devices & Instruments median (#376 of 472)
No single metric tells the full story. See the FRA:46K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
94GF Score
Get the complete analysis for FRA:46K
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:46K has been successfully added to your 
